Forschung

Forschung/Entwicklung

Akuelle Veröffentlichungen

Nachfolgend finden Sie eine Auswahl der Fachpublikationen von Herrn Prof. Dr. med. Aristoteles Giaogounidis, die in internationalen Literaturverzeichnissen erscheinen sind:

Publikationen 2017

1: Giagounidis A. Current treatment algorithm for the management of lower-riskMDS. Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):453-459. doi: 10.1182/asheducation-2017.1.453. Review. PubMed PMID: 29222293.

2: Valent P, Orazi A, Steensma DP, Ebert BL, Haase D, Malcovati L, van deLoosdrecht AA, Haferlach T, Westers TM, Wells DA, Giagounidis A, Loken M, Orfao A, Lübbert M, Ganser A, Hofmann WK, Ogata K, Schanz J, BÃ©nÃ© MC, Hoermann G, SperrWR, Sotlar K, Bettelheim P, Stauder R, Pfeilstöcker M, Horny HP, Germing U, Greenberg P, Bennett JM. Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. Oncotarget. 2017 Jul 5;8(43):73483-73500. doi: 10.18632/oncotarget.19008. eCollection 2017 Sep 26. PubMed PMID: 29088721; PubMed Central PMCID: PMC5650276.

3: Metzelder SK, Schroeder T, Lübbert M, Ditschkowski M, Götze K, Scholl S, Meyer RG, Dreger P, Basara N, Fey MF, Salih HR, Finck A, Pabst T, Giagounidis A, Kobbe G, Wollmer E, Finke J, Neubauer A, Burchert A. Long-term survival ofsorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation. Eur J Cancer. 2017Nov;86:233-239. doi: 10.1016/j.ejca.2017.09.016. Epub 2017 Oct 18. PubMed PMID: 29055209.

4: Platzbecker U, Germing U, Götze KS, Kiewe P, Mayer K, Chromik J, Radsak M,Wolff T, Zhang X, Laadem A, Sherman ML, Attie KM, Giagounidis A. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes(PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. Lancet Oncol. 2017 Oct;18(10):1338-1347. doi: 10.1016/S1470-2045(17)30615-0. Epub 2017 Sep 1. PubMed PMID: 28870615.

5: Mitsimponas N, Mitsogianni M, Crespo F, Hartmann KA, Diederich S,Klosterhalfen B, Giagounidis A. Isolated Splenic Metastasis from Non-Small-Cell Lung Cancer: A Case Report and Review of the Literature. Case Rep Oncol. 2017 Jul 11;10(2):638-643. doi: 10.1159/000478002. eCollection 2017 May-Aug. PubMed PMID: 28868024; PubMed Central PMCID: PMC5567076.

6: Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mittelman M, Muus P, Nimer SD, Hellström-Lindberg E, Powell BL, Guerci-Bresler A, Sekeres MA, Deeg HJ, Del CaÃ±izo C, Greenberg PL, Shammo JM, Skikne B, Yu X, List AF. Clinicalcharacteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q). J Hematol Oncol. 2017Jun 26;10(1):131. doi: 10.1186/s13045-017-0491-2. PubMed PMID: 28651604; PubMed Central PMCID: PMC5485496.

7: Jann JC, Nowak D, Nolte F, Fey S, Nowak V, Obländer J, Pressler J, Palme I,Xanthopoulos C, Fabarius A, Platzbecker U, Giagounidis A, Götze K, Letsch A,Haase D, Schlenk R, Bug G, Lübbert M, Ganser A, Germing U, Haferlach C, Hofmann WK, Mossner M. Accurate quantification of chromosomal lesions via short tandem repeat analysis using minimal amounts of DNA. J Med Genet. 2017Sep;54(9):640-650. doi: 10.1136/jmedgenet-2017-104528. Epub 2017 Jun 9. PubMed PMID: 28600436; PubMed Central PMCID: PMC5574397.

8: Braulke F, Schulz X, Germing U, Schuler E, Platzbecker U, Nolte F, Hofmann WK, Giagounidis A, Götze K, Lübbert M, Schlenk RF, Schanz J, Bacher U, Ganser A, Büsche G, Letsch A, Schafhausen P, Bug G, Brümmendorf TH, Haas R, Trümper L, Shirneshan K, Haase D. Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial. Ann Hematol. 2017 Jun;96(6):887-894. doi: 10.1007/s00277-017-2983-0. Epub 2017 Apr 3. PubMed PMID: 28374162.

9: Strupp C, Nachtkamp K, Hildebrandt B, Giagounidis A, Haas R, Gattermann N,Bennett JM, Aul C, Germing U. New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): Characteristics of refined MDS types. Leuk Res. 2017 Jun;57:78-84. doi: 10.1016/j.leukres.2017.02.008. Epub 2017 Feb 27. PubMed PMID: 28324772.

10. Dr. Hellmich, Nikolai. Behandlung myelodysplastischer Syndrome mit del(5q) Aberration mit niedrigdosierter Cytarabintherapie, https://docserv.uni-duesseldorf.de/servlets/DocumentServlet?id=38935

Pubilationen vor 2017

1.	Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents.
	Santini V, Almeida A, Giagounidis A, Gröpper S, Jonasova A, Vey N, Mufti GJ, Buckstein R, Mittelman M, Platzbecker U, Shpilberg O, Ram R, Del CaÃ±izo C, Gattermann N, Ozawa K, RisueÃ±o A, MacBeth KJ, Zhong J, SÃ©guy F, Hoenekopp A, Beach CL, Fenaux P.
	J Clin Oncol. 2016 Sep 1;34(25):2988-96. doi: 10.1200/JCO.2015.66.0118. Epub 2016 Jun 27.
	PMID: 27354480 [PubMed - in process]
	Similar articles

2.	Transfusion Independency and Histological Remission in a Patient with Advanced Primary Myelofibrosis Receiving Iron-Chelation Therapy with Deferasirox.
	Groepper S, Schlue J, Haferlach C, Giagounidis A.
	Oncol Res Treat. 2016;39(6):384-7. doi: 10.1159/000446029. Epub 2016 May 25.
	PMID: 27260366 [PubMed - in process]
	Similar articles

3.	Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion-dependent anemia and thrombocytopenia.
	Garcia-Manero G, Almeida A, Giagounidis A, Platzbecker U, Garcia R, Voso MT, Larsen SR, Valcarcel D, Silverman LR, Skikne B, Santini V.
	BMC Hematol. 2016 May 3;16:12. doi: 10.1186/s12878-016-0049-5. eCollection 2016.
	PMID: 27148452 [PubMed] Free PMC Article
	Similar articles

4.	Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS).
	Mossner M, Jann JC, Nowak D, Platzbecker U, Giagounidis A, Götze K, Letsch A, Haase D, Shirneshan K, Braulke F, Schlenk RF, Haferlach T, Schafhausen P, Bug G, Lübbert M, Ganser A, Büsche G, Schuler E, Nowak V, Pressler J, Obländer J, Fey S, Müller N, Lauinger-Lörsch E, Metzgeroth G, Weiß C, Hofmann WK, Germing U, Nolte F.
	Leukemia. 2016 Sep;30(9):1956-9. doi: 10.1038/leu.2016.111. Epub 2016 May 2. No abstract available.
	PMID: 27133825 [PubMed - in process]
	Similar articles

5.	Causes of death in 2877 patients with myelodysplastic syndromes.
	Nachtkamp K, Stark R, Strupp C, Kündgen A, Giagounidis A, Aul C, Hildebrandt B, Haas R, Gattermann N, Germing U.
	Ann Hematol. 2016 May;95(6):937-44. doi: 10.1007/s00277-016-2649-3. Epub 2016 Mar 30.
	PMID: 27025507 [PubMed - in process]
	Similar articles

6.	Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies.
	Borthakur G, Popplewell L, Boyiadzis M, Foran J, Platzbecker U, Vey N, Walter RB, Olin R, Raza A, Giagounidis A, Al-Kali A, Jabbour E, Kadia T, Garcia-Manero G, Bauman JW, Wu Y, Liu Y, Schramek D, Cox DS, Wissel P, Kantarjian H.
	Cancer. 2016 Jun 15;122(12):1871-9. doi: 10.1002/cncr.29986. Erratum in: Cancer. 2016 Oct 15;122(20):3246.
	PMID: 26990290 [Unknown status]
	Similar articles

7.	[Leukemia research in Germany: the Competence Network Acute and Chronic Leukemias].
	Kossak-Roth U, Saußele S, Aul C, Büchner T, Döhner H, Dugas M, Ehninger G, Ganser A, Giagounidis A, Gökbuget N, Griesshammer M, Hasford J, Heuser M, Hiddemann W, Hochhaus A, Hoelzer D, Niederwieser D, Reiter A, Röllig C, Hehlmann R.
	Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2016 Apr;59(4):444-53. doi: 10.1007/s00103-016-2315-x. German.
	PMID: 26979719 [PubMed - in process]
	Similar articles

8.	Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia.
	Büchner T, Krug UO, Peter Gale R, Heinecke A, Sauerland MC, Haferlach C, Schnittger S, Haferlach T, Müller-Tidow C, Stelljes M, Mesters RM, Serve HL, Braess J, Spiekermann K, Staib P, Grüneisen A, Reichle A, Balleisen L, Eimermacher H, Giagounidis A, Rasche H, Lengfelder E, Görlich D, Faldum A, Köpcke W, Hehlmann R, Wörmann BJ, Berdel WE, Hiddemann W.
	Leukemia. 2016 Aug;30(8):1781-4. doi: 10.1038/leu.2016.54. Epub 2016 Mar 11. No abstract available.
	PMID: 26965440 [PubMed - in process]
	Similar articles

9.	Impaired formation of erythroblastic islands is associated with erythroid failure and poor prognosis in a significant proportion of patients with myelodysplastic syndromes.
	Buesche G, Teoman H, Giagounidis A, Göhring G, Schlegelberger B, Ganser A, Aul C, Kreipe HH.
	Haematologica. 2016 May;101(5):e177-81. doi: 10.3324/haematol.2015.129015. Epub 2016 Mar 4. No abstract available.
	PMID: 26944473 [PubMed - in process] Free PMC Article
	Similar articles

10.	Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia.
	Krug U, Berdel WE, Gale RP, Haferlach C, Schnittger S, Müller-Tidow C, Braess J, Spiekermann K, Staib P, Beelen D, Serve H, Schliemann C, Stelljes M, Balleisen L, Maschmeyer G, Grüneisen A, Eimermacher H, Giagounidis A, Rasche H, Hehlmann R, Lengfelder E, Thiel E, Reichle A, Aul C, Ludwig WD, Kern W, Haferlach T, Köpcke W, Görlich D, Sauerland MC, Heinecke A, Wörmann BJ, Hiddemann W, Büchner T.
	Leukemia. 2016 Jun;30(6):1230-6. doi: 10.1038/leu.2016.25. Epub 2016 Feb 9.
	PMID: 26859081 [PubMed - in process]
	Similar articles

11.	Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
	Platzbecker U, Wong RS, Verma A, Abboud C, Araujo S, Chiou TJ, Feigert J, Yeh SP, Götze K, Gorin NC, Greenberg P, Kambhampati S, Kim YJ, Lee JH, Lyons R, Ruggeri M, Santini V, Cheng G, Jang JH, Chen CY, Johnson B, Bennett J, Mannino F, Kamel YM, Stone N, Dougherty S, Chan G, Giagounidis A.
	Lancet Haematol. 2015 Oct;2(10):e417-26. doi: 10.1016/S2352-3026(15)00149-0. Epub 2015 Oct 1.
	PMID: 26686043 [PubMed - in process]
	Similar articles

12.	Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5).
	Schuler E, Giagounidis A, Haase D, Shirneshan K, Büsche G, Platzbecker U, Nolte F, Götze K, Schlenk RF, Ganser A, Letsch A, Braulke F, Lübbert M, Bug G, Schafhausen P, Bacher U, Gattermann N, Wulfert M, Haas R, Germing U.
	Leukemia. 2016 Jul;30(7):1580-2. doi: 10.1038/leu.2015.340. Epub 2015 Dec 15. No abstract available.
	PMID: 26668126 [PubMed - in process]
	Similar articles

13.	Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS.
	List AF, Bennett JM, Sekeres MA, Skikne B, Fu T, Shammo JM, Nimer SD, Knight RD, Giagounidis A.
	Leukemia. 2015 Dec;29(12):2452. doi: 10.1038/leu.2015.312. No abstract available.
	PMID: 26648407 [PubMed]
	Similar articles

14.	Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group.
	Lübbert M, Suciu S, Hagemeijer A, Rüter B, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Muus P, Pflüger KH, Schaefer HE, Bogatyreva L, Aul C, de Witte T, Ganser A, Becker H, Huls G, van der Helm L, Vellenga E, Baron F, Marie JP, Wijermans PW; EORTC Leukemia Group and the German MDS Study Group.
	Ann Hematol. 2016 Jan;95(2):191-9. doi: 10.1007/s00277-015-2547-0. Epub 2015 Nov 23.
	PMID: 26596971 [PubMed - indexed for MEDLINE]
	Similar articles

15.	Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
	Röllig C, Serve H, Hüttmann A, Noppeney R, Müller-Tidow C, Krug U, Baldus CD, Brandts CH, Kunzmann V, Einsele H, Krämer A, Schäfer-Eckart K, Neubauer A, Burchert A, Giagounidis A, Krause SW, Mackensen A, Aulitzky W, Herbst R, Hänel M, Kiani A, Frickhofen N, Kullmer J, Kaiser U, Link H, Geer T, Reichle A, Junghanß C, Repp R, Heits F, Dürk H, Hase J, Klut IM, Illmer T, Bornhäuser M, Schaich M, Parmentier S, Görner M, Thiede C, von Bonin M, Schetelig J, Kramer M, Berdel WE, Ehninger G; Study Alliance Leukaemia.
	Lancet Oncol. 2015 Dec;16(16):1691-9. doi: 10.1016/S1470-2045(15)00362-9. Epub 2015 Nov 6.
	PMID: 26549589 [PubMed - indexed for MEDLINE]
	Similar articles

16.	Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the Study Alliance Leukemia.
	Müller-Tidow C, Tschanter P, Röllig C, Thiede C, Koschmieder A, Stelljes M, Koschmieder S, Dugas M, Gerss J, Butterfaß-Bahloul T, Wagner R, Eveslage M, Thiem U, Krause SW, Kaiser U, Kunzmann V, Steffen B, Noppeney R, Herr W, Baldus CD, Schmitz N, Götze K, Reichle A, Kaufmann M, Neubauer A, Schäfer-Eckart K, Hänel M, Peceny R, Frickhofen N, Kiehl M, Giagounidis A, Görner M, Repp R, Link H, Kiani A, Naumann R, Brümmendorf TH, Serve H, Ehninger G, Berdel WE, Krug U; Study Alliance Leukemia Group.
	Leukemia. 2016 Mar;30(3):555-61. doi: 10.1038/leu.2015.306. Epub 2015 Nov 2.
	PMID: 26522083 [PubMed - indexed for MEDLINE]
	Similar articles

17.	Telomere dynamics in patients with del (5q) MDS before and under treatment with lenalidomide.
	Beier F, Masouleh BK, Buesche G, Ventura Ferreira MS, Schneider RK, Ziegler P, Wilop S, Vankann L, Gattermann N, Platzbecker U, Giagounidis A, Götze KS, Nolte F, Hofmann WK, Haase D, Kreipe H, Panse J, Blasco MA, Germing U, Brümmendorf TH.
	Leuk Res. 2015 Sep 21. pii: S0145-2126(15)30380-5. doi: 10.1016/j.leukres.2015.09.003. [Epub ahead of print]
	PMID: 26427727 [PubMed - as supplied by publisher]
	Similar articles

18.	Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG).
	Becker H, Suciu S, Rüter BH, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Muus P, Pflüger KH, Hagemeijer A, Schaefer HE, Fiaccadori V, Baron F, Ganser A, Aul C, de Witte T, Wijermans PW, Lübbert M.
	Ann Hematol. 2015 Dec;94(12):2003-13. doi: 10.1007/s00277-015-2489-6. Epub 2015 Sep 24.
	PMID: 26400023 [PubMed - indexed for MEDLINE]
	Similar articles

19.	Frequency of del(12p) is commonly underestimated in myelodysplastic syndromes: Results from a German diagnostic study in comparison with an international control group.
	Braulke F, Müller-Thomas C, Götze K, Platzbecker U, Germing U, Hofmann WK, Giagounidis AA, Lübbert M, Greenberg PL, Bennett JM, SolÃ© F, Slovak ML, Ohyashiki K, Le Beau MM, Tüchler H, Pfeilstöcker M, Hildebrandt B, Aul C, Stauder R, Valent P, Fonatsch C, Bacher U, Trümper L, Haase D, Schanz J.
	Genes Chromosomes Cancer. 2015 Dec;54(12):809-17. doi: 10.1002/gcc.22292. Epub 2015 Sep 10.
	PMID: 26355708 [PubMed - indexed for MEDLINE]
	Similar articles

20.	Where Does Lenalidomide Fit in Non-del(5q) MDS?
	Giagounidis A.
	Curr Hematol Malig Rep. 2015 Sep;10(3):303-8. doi: 10.1007/s11899-015-0275-0. Review.
	PMID: 26169489 [PubMed - indexed for MEDLINE]
	Similar articles

21.	CSNK1A1 mutations and gene expression analysis in myelodysplastic syndromes with del(5q).
	Bello E, Pellagatti A, Shaw J, Mecucci C, KuÅ¡ec R, Killick S, Giagounidis A, Raynaud S, Calasanz MJ, Fenaux P, Boultwood J.
	Br J Haematol. 2015 Jun 18. doi: 10.1111/bjh.13563. [Epub ahead of print]
	PMID: 26085061 [PubMed - as supplied by publisher] Free PMC Article
	Similar articles

22.	Change of prognosis of patients with myelodysplastic syndromes during the last 30 years.
	Neukirchen J, Nachtkamp K, Schemenau J, Aul C, Giagounidis A, Strupp C, Kuendgen A, Kobbe G, Haas R, Germing U.
	Leuk Res. 2015 Jul;39(7):679-83. doi: 10.1016/j.leukres.2015.04.001. Epub 2015 Apr 15.
	PMID: 25929166 [PubMed - indexed for MEDLINE]
	Similar articles

23.	Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes.
	Gerstung M, Pellagatti A, Malcovati L, Giagounidis A, Porta MG, Jädersten M, Dolatshad H, Verma A, Cross NC, Vyas P, Killick S, Hellström-Lindberg E, Cazzola M, Papaemmanuil E, Campbell PJ, Boultwood J.
	Nat Commun. 2015 Jan 9;6:5901. doi: 10.1038/ncomms6901.
	PMID: 25574665 [PubMed - indexed for MEDLINE] Free PMC Article
	Similar articles

24.	Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group.
	Braulke F, Platzbecker U, Müller-Thomas C, Götze K, Germing U, Brümmendorf TH, Nolte F, Hofmann WK, Giagounidis AA, Lübbert M, Greenberg PL, Bennett JM, SolÃ© F, Mallo M, Slovak ML, Ohyashiki K, Le Beau MM, Tüchler H, Pfeilstöcker M, Nösslinger T, Hildebrandt B, Shirneshan K, Aul C, Stauder R, Sperr WR, Valent P, Fonatsch C, Trümper L, Haase D, Schanz J.
	Haematologica. 2015 Feb;100(2):205-13. doi: 10.3324/haematol.2014.110452. Epub 2014 Oct 24.
	PMID: 25344522 [PubMed - indexed for MEDLINE] Free PMC Article
	Similar articles

25.	Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial.
	Platzbecker U, Sekeres MA, Kantarjian H, Giagounidis A, Mufti GJ, Jia C, Yang AS, Fenaux P.
	Leukemia. 2014 Dec;28(12):2418-21. doi: 10.1038/leu.2014.253. Epub 2014 Sep 2. No abstract available.
	PMID: 25179731 [PubMed - indexed for MEDLINE] Free PMC Article
	Similar articles

26.	Impact of self-administration of romiplostim by patients with chronic immune thrombocytopenia compared with administration by a healthcare provider.
	Selleslag D, Bird R, Altomare I, Giagounidis A, Janssens A, Pabinger I, Pullarkat V, Wei H, Kreuzbauer G.
	Eur J Haematol. 2015 Feb;94(2):169-76. doi: 10.1111/ejh.12415. Epub 2014 Aug 8.
	PMID: 25039799 [PubMed - indexed for MEDLINE]
	Similar articles

27.	Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk myelodysplastic syndromes.
	Sekeres MA, Giagounidis A, Kantarjian H, Mufti GJ, Fenaux P, Jia C, Yang AS, Platzbecker U.
	Br J Haematol. 2014 Nov;167(3):337-45. doi: 10.1111/bjh.13037. Epub 2014 Jul 14.
	PMID: 25039607 [PubMed - indexed for MEDLINE]
	Similar articles

28.	Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study.
	Giagounidis A, Mufti GJ, Mittelman M, Sanz G, Platzbecker U, Muus P, Selleslag D, Beyne-Rauzy O, te Boekhorst P, del CaÃ±izo C, Guerci-Bresler A, Nilsson L, Lübbert M, Quesnel B, Ganser A, Bowen D, Schlegelberger B, Göhring G, Fu T, Benettaib B, Hellström-Lindberg E, Fenaux P.
	Eur J Haematol. 2014 Nov;93(5):429-38. doi: 10.1111/ejh.12380. Epub 2014 Jun 9.
	PMID: 24813620 [PubMed - indexed for MEDLINE] Free PMC Article
	Similar articles

29.	Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia.
	Giagounidis A, Mufti GJ, Fenaux P, Sekeres MA, Szer J, Platzbecker U, Kuendgen A, Gaidano G, Wiktor-Jedrzejczak W, Hu K, Woodard P, Yang AS, Kantarjian HM.
	Cancer. 2014 Jun 15;120(12):1838-46. doi: 10.1002/cncr.28663. Epub 2014 Apr 4.
	PMID: 24706489 [PubMed - indexed for MEDLINE] Free PMC Article
	Similar articles

30.	p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).
	Saft L, Karimi M, Ghaderi M, Matolcsy A, Mufti GJ, Kulasekararaj A, Göhring G, Giagounidis A, Selleslag D, Muus P, Sanz G, Mittelman M, Bowen D, Porwit A, Fu T, Backstrom J, Fenaux P, MacBeth KJ, Hellström-Lindberg E.
	Haematologica. 2014 Jun;99(6):1041-9. doi: 10.3324/haematol.2013.098103. Epub 2014 Mar 28.
	PMID: 24682512 [PubMed - indexed for MEDLINE] Free PMC Article
	Similar articles

31.	[Immune thrombocytopenia -- onkopedic guidelines update: recommendations of a joint working group of the DGHO, ÖGHO, SGH + SSH and GPOH].
	Matzdorff A, Eberl W, Giagounidis A, Imbach P, Pabinger I, Wörmann B.
	Oncol Res Treat. 2014;37 Suppl 2:6-25. doi: 10.1159/000356910. German. No abstract available.
	PMID: 24613966 [PubMed - indexed for MEDLINE]
	Similar articles

32.	Morphology, cytogenetics and classification of MDS.
	Giagounidis A, Haase D.
	Best Pract Res Clin Haematol. 2013 Dec;26(4):337-53. doi: 10.1016/j.beha.2013.09.004. Epub 2013 Oct 1. Review.
	PMID: 24507811 [PubMed - indexed for MEDLINE]
	Similar articles

33.	Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study.
	Neukirchen J, Lauseker M, Blum S, Giagounidis A, Lübbert M, Martino S, Siragusa S, Schlenk RF, Platzbecker U, Hofmann WK, Götze K, Palumbo GA, Magrin S, Kündgen A, Aul C, Hildebrandt B, Hasford J, Kobbe G, Haas R, Germing U.
	Leuk Res. 2014 Jan;38(1):57-64. doi: 10.1016/j.leukres.2013.10.013. Epub 2013 Oct 26.
	PMID: 24238640 [PubMed - indexed for MEDLINE]
	Similar articles

34.	Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients.
	Platzbecker U, Al-Ali HK, Gattermann N, Haase D, Janzen V, Krauter J, Götze K, Schlenk R, Nolte F, Letsch A, Ottmann OG, Kündgen A, Lübbert M, Germing U, Wermke M, Reinhard H, Weiss C, Lieder K, Ehninger G, Leismann O, Giagounidis A.
	Leukemia. 2014 Mar;28(3):696-8. doi: 10.1038/leu.2013.325. Epub 2013 Nov 4. No abstract available.
	PMID: 24186004 [PubMed - indexed for MEDLINE]
	Similar articles

35.	Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS.
	List AF, Bennett JM, Sekeres MA, Skikne B, Fu T, Shammo JM, Nimer SD, Knight RD, Giagounidis A; MDS-003 Study Investigators.
	Leukemia. 2014 May;28(5):1033-40. doi: 10.1038/leu.2013.305. Epub 2013 Oct 22. Erratum in: Leukemia. 2015 Dec;29(12):2452.
	PMID: 24150217 [PubMed - indexed for MEDLINE] Free PMC Article
	Similar articles

36.	Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes.
	Giagounidis A, Mufti GJ, Fenaux P, Germing U, List A, MacBeth KJ.
	Ann Hematol. 2014 Jan;93(1):1-11. doi: 10.1007/s00277-013-1863-5. Epub 2013 Sep 10. Review.
	PMID: 24018623 [PubMed - indexed for MEDLINE] Free PMC Article
	Similar articles

37.	Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes.
	Pellagatti A, Benner A, Mills KI, Cazzola M, Giagounidis A, Perry J, Malcovati L, Della Porta MG, Jädersten M, Verma A, McDonald EJ, Killick S, Hellström-Lindberg E, Bullinger L, Wainscoat JS, Boultwood J.
	J Clin Oncol. 2013 Oct 1;31(28):3557-64. doi: 10.1200/JCO.2012.45.5626. Epub 2013 Sep 3.
	PMID: 24002510 [PubMed - indexed for MEDLINE] Free Article
	Similar articles